FDA approves Roche ’s Avastin (bevacizumab) plus chemotherapy as a treatment for women with advanced ovarian cancer following initial surgery

Roche today announced that the US Food and Drug Administration (FDA) has approved Avastin ® (bevacizumab) in combination with chemotherapy (carboplatin and paclitaxel), followed by Avastin as a single agent, for the treatment of women with advanced (stage III or IV) ovarian cancer following initial surgical resection.
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news

Related Links:

Publication date: Available online 15 March 2019Source: European Journal of Obstetrics &Gynecology and Reproductive BiologyAuthor(s): V. Lavoue, C. Huchon, C. Akladios, P. Alfonsi, N. Bakrin, M. Ballester, S. Bendifallah, P.A. Bolze, F. Bonnet, C. Bourgin, N. Chabbert-Buffet, P. Collinet, B. Courbiere, T. De la motte rouge, M. Devouassoux-Shisheboran, C. Falandry, G. Ferron, L. Fournier, L. Gladieff, F. GolfierAbstractAn MRI is recommended for an ovarian mass that is indeterminate on ultrasound. The ROMA score (combining CA125 and HE4) can also be calculated (Grade A). In presumed early-stage ovarian or tubal cancers, ...
Source: European Journal of Obstetrics and Gynecology and Reproductive Biology - Category: OBGYN Source Type: research
In conclusion, although functioning stromal cells of ovarian cancer are usually thought to be non-neoplastic, some may share an origin with carcinoma cells. PMID: 30867798 [PubMed]
Source: Oncology Letters - Category: Cancer & Oncology Tags: Oncol Lett Source Type: research
We examined the effect of catechin and cisplatin on human ovarian cancer cells’ SKOV-3 viability. It was also studied whether preincubation with catechin modulates drug resistance revealed by SKOV-3 cells. Catechin at concentratio ns up to 200 µM has been shown to be slightly toxic to the tested cells. Analysis of cells after preincubation with catechin revealed increased cytotoxicity of cisplatin compared to the cells treated only with cytostatic and changed expression of MDR-related proteins. Pre-treatment with catechin enhanced cisplatin cytotoxicity by promoting apoptosis and changing activity of mem...
Source: Medicinal Chemistry Research - Category: Chemistry Source Type: research
Publication date: Available online 15 March 2019Source: Redox BiologyAuthor(s): Aaron Wilson, Vijay Menon, Zubair Khan, Asim Alam, Larisa Litovchick, Vasily YakovlevAbstractRecently, clinical development of PARP inhibitors (PARPi) expanded from using them as a single agent to combining them with DNA-damaging therapy to derive additional therapeutic benefit from stimulated DNA damage. Furthermore, inhibiting PARP in cancers with BRCA1/2 mutations has been shown to be an effective synthetic lethality approach either as a single agent or in combination with the different DNA damaging agents: chemotherapy or ionizing radiation...
Source: Redox Biology - Category: Biology Source Type: research
In conclusion, the findings of the present study suggested several underlying miRNA targets for improving the chemotherapy sensitivity of OC. PMID: 30864705 [PubMed - as supplied by publisher]
Source: Molecular Medicine Reports - Category: Molecular Biology Tags: Mol Med Rep Source Type: research
Publication date: 12 March 2019Source: Cell Reports, Volume 26, Issue 11Author(s): Ilana Chefetz, Edward Grimley, Kun Yang, Linda Hong, Ekaterina V. Vinogradova, Radu Suciu, Ilya Kovalenko, David Karnak, Cynthia A. Morgan, Mikhail Chtcherbinine, Cameron Buchman, Brandt Huddle, Scott Barraza, Meredith Morgan, Kara A. Bernstein, Euisik Yoon, David B. Lombard, Andrea Bild, Geeta Mehta, Iris RomeroSummaryOvarian cancer is typified by the development of chemotherapy resistance. Chemotherapy resistance is associated with high aldehyde dehydrogenase (ALDH) enzymatic activity, increased cancer “stemness,” and expr...
Source: Cell Reports - Category: Cytology Source Type: research
Authors: Han X, Wang W, He J, Jiang L, Li X Abstract Osteosarcoma (OS) is the most common bone malignancy, and is particularly prevalent in children and adolescents. OS is an aggressive tumor with a tendency to metastasize and invade to para-carcinoma tissues. The primary treatment for this tumor is a combination of surgery and chemotherapy. However, the prognosis remains poor due to chemoresistance and early metastasis. Osteopontin (OPN), a multifunctional secreted protein, has emerged as an important potential biomarker for diagnosing and treating cancer. The overexpression of OPN has been found in numerous malig...
Source: Oncology Letters - Category: Cancer & Oncology Tags: Oncol Lett Source Type: research
Shaylee Bedward, 25, from Bloomington, Indiana, was diagnosed with stage 3 ovarian cancer in October 2017. After chemotherapy didn't work, she underwent a hysterectomy.
Source: the Mail online | Health - Category: Consumer Health News Source Type: news
Timing of menopause is an indicator of ovarian function and has important health implications. Natural menopause is commonly defined as the time when a woman has experienced 12 consecutive months of amenorrhoea without obvious cause [1], such as removal of both ovaries (bilateral oophorectomy), chemotherapy or radiotherapy for cancer. The International collaboration on the Life course Approach to reproductive health and Chronic disease Events (InterLACE) [2] recently reported that the average age at natural menopause across 21 studies from 10 countries ranged from 47 to 53 years, varying across ethnic groups from 48 years ...
Source: Maturitas - Category: Primary Care Authors: Source Type: research
chel L O’Donnell Dysfunctional homologous recombination DNA repair (HRR), frequently due to BRCA mutations, is a determinant of sensitivity to platinum chemotherapy and poly(ADP-ribose) polymerase inhibitors (PARPi). In cultures of ovarian cancer cells, we have previously shown that HRR function, based upon RAD51 foci quantification, correlated with growth inhibition ex vivo induced by rucaparib (a PARPi) and 12-month survival following platinum chemotherapy. The aim of this study was to determine the feasibility of measuring HRR dysfunction (HRD) in other tumours, in order to estimate the frequency and hence wid...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
More News: Avastin | Cancer | Cancer & Oncology | Chemotherapy | Food and Drug Administration (FDA) | Ovarian Cancer | Ovaries | Pharmaceuticals | Women